Cambrex Announces New Liquid-Phase Peptide Synthesis Manufacturing Technology USA - English USA - English USA - español Japan - Japanese
Jersey Desk/10276520

Trending...
EAST RUTHERFORD, N.J., Sept. 19, 2024 ~ Cambrex, a global contract development and manufacturing organization (CDMO), has recently announced a breakthrough in peptide synthesis technology. The company's subsidiary, Snapdragon Chemistry, has successfully developed a new liquid-phase peptide synthesis (LPPS) technology that eliminates the need for specialized solid-phase reactors.

This innovative LPPS technology utilizes traditional active pharmaceutical ingredient (API) batch reactors and continuous flow, significantly reducing solvent demand and excess reagents compared to standard solid-state peptide synthesis processes. This not only makes the process more cost-efficient but also more environmentally sustainable.

Dr. Matt Bio, Chief Scientific Officer at Cambrex, stated that the company has been investing in research and development of complex synthetics for several years with the goal of reducing economic and environmental impacts in peptide and oligonucleotide manufacturing. He added that their new LPPS technology offers a more efficient and sustainable solution compared to traditional methods.

More on Jersey Desk
The LPPS technology can support peptides up to 12 residues long, while larger peptides can be assembled using a convergent fragment coupling approach in liquid phase. This allows for scalability similar to traditional small molecules.

In addition to LPPS, Cambrex has also developed unique capabilities in peptide and protein crystallization. They have a screening platform specifically designed for discovering crystalline forms of peptides and proteins. Crystallization can improve product quality and stability while reducing the need for time-consuming preparative chromatography and lyophilization.

Thomas Loewald, CEO at Cambrex, emphasized the importance of providing industry-leading solutions for developing and scaling peptide-based therapies. He stated that their continued investment in R&D across complex synthetic modalities will include further technology development for peptides as well as research on the application of artificial intelligence in optimizing oligonucleotide processes.

Cambrex's new LPPS technology is expected to have a significant impact on the pharmaceutical industry by offering a more efficient and sustainable method for synthesizing peptides. With their continued investment in research and development, the company is poised to remain a leader in complex synthetic modalities.
Filed Under: Business

Show All News | Report Violation

0 Comments

Latest on Jersey Desk